CLAIMS

1. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the treatment of irregular sleep-wake rhythm disorder in a subject.

2. The use according to claim 1, wherein the irregular sleep-wake rhythm disorder is due to traumatic brain injury.

3. The use according to claim 1, wherein the irregular sleep-wake rhythm disorder is due to at least one neurodevelopmental disorder.

4. The use according to claim 1, wherein the irregular sleep-wake rhythm disorder is due to dementia due to Alzheimer's disease and/or related disorders.

5. The use according to claim 1, wherein the irregular sleep-wake rhythm disorder is due to dementia due to Alzheimer's disease.

6. The use according to any one of claims 1 to 5, wherein the subject suffers from at least one other circadian rhythm sleep disorder in addition to irregular sleep-wake rhythm disorder.

7. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for improving continuity of nocturnal sleep in a subject with irregular sleep-wake rhythm disorder.

8. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for improving behaviors and cognitive difficulties associated with irregular sleep-wake rhythm disorder in a subject.

9. Use of a compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the treatment of excessive daytime sleepiness and/or napping in a subject with irregular sleep-wake rhythm disorder.

10. The use according to any one of claims 1 to 9, wherein the subject experiences a stabilization of one or more circadian rhythms.

11. The use according to any one of claims 1 to 9, wherein the subject experiences an improvement of one or more circadian rhythms.

12. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the treatment of at one least circadian rhythm sleep disorder in a subject with dementia due to Alzheimer’s disease and/or related disorders.

13. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the treatment of at least one circadian rhythm sleep disorder in a subject with mild cognitive impairment due to Alzheimer’s disease.

14. The use according to claim 12 or 13, wherein the at least one circadian rhythm sleep disorder is chosen from sleep disruption, sleep-wake fragmentation, circadian rhythm sleep disorder, and irregular sleep-wake rhythm disorder.

15. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the improvement of continuity of nocturnal sleep in a subject with dementia due to Alzheimer's disease and/or related disorders.

16. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the improvement of continuity of nocturnal sleep in a subject with mild cognitive impairment due to Alzheimer's disease.

17. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the improvement of at least one behavior and/or cognitive difficulty associated with dementia in a subject with dementia due to Alzheimer's disease and/or related disorders.

18. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the improvement of at least one behavior and/or cognitive difficulty associated with dementia in a subject with mild cognitive impairment due to Alzheimer's disease.

19. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of

the foregoing in the manufacture of a medicament for the treatment of excessive daytime sleepiness and/or napping in a subject with dementia due to Alzheimer's disease and/or related disorders.

20. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the treatment of excessive daytime sleepiness and/or napping in a subject with mild cognitive impairment due to Alzheimer's disease.

21. The use according to any one of claims 12 to 20, wherein the subject experiences a clinical stabilization in cognitive impairment due to Alzheimer's disease and/or related disorders.

22. The use according to any one of claims 12 to 21, wherein the subject experiences a clinical improvement in the cognitive impairment due to Alzheimer's disease and/or related disorders.

23. The use according to any one of claims 12 to 22, wherein the subject experiences a clinical reduction in rate of decline in the cognitive impairment due to Alzheimer's disease and/or related disorders.

24. The use according to any one of claims 12 to 23, wherein the subject experiences a clinical stabilization of the dementia due to Alzheimer's disease and/or related disorders.

25. The use according to any one of claims 12 to 24, wherein the subject experiences a clinical improvement of the dementia due to Alzheimer's disease and/or related disorders.

26. The use according to any one of claims 12 to 25, wherein the subject experiences a clinical reduction in rate of decline in dementia due to Alzheimer's disease and/or related disorders.

27. The use according to any one of claims 12 to 26, wherein the subject experiences a decrease in behavioral disturbances.

28. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the stabilization of one or more circadian rhythms in a subject.

29. Use of at least one compound chosen from compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), and solvates of any of the foregoing in the manufacture of a medicament for the improvement of one or more circadian rhythms in a subject.

30. The use according to any one of claims 1 to 29, wherein sleep is consolidated during the nighttime hours.

31. The use according to any one of claim 1 to 30, wherein wakefulness is consolidated during the daytime hours.

32. The use according to any one of claims 1 to 31, wherein the subject experiences an increase in sleep efficiency.

33. The use according to any one of claims 1 to 32, wherein the subject experiences an increase in wake efficiency.

34. The use according to any one of claims 1 to 33, wherein the subject experiences a decrease in daytime sleepiness and/or daytime napping.

35. The use according to any one of claims 1 to 34, wherein the subject experiences an increase in daytime alertness.

36. The use according to any one of claims 1 to 35, wherein the subject experiences a reduction in the accumulation of Aβ plaque in the brain.

37. The use according to any one of claims 1 to 36, wherein the subject experiences a reduction of soluble toxic Aβ aggregates.